Biosense Webster
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application for the Johnson & Johnson subsidiary's Stockert 70 radio frequency generator for cardiac ablation is approved by FDA May 31. Indicated for use "with a Biosense Webster diagnostic/ablation deflectable tip catheter to deliver RF energy during cardiac ablation procedures," the Stockert is the third generator for cardiac ablation to reach the U.S. market, joining Medtronic's Atakr and Boston Scientific's EPT-1000